Related Experiment Videos
Practical application of guinea pig telemetry system for QT evaluation
Motohiro Shiotani1, Takuma Harada, Junko Abe
1Worldwide Safety Sciences, Pfizer Global Research and Development, Nagoya Laboratories, Pfizer Japan Inc., Aichi.
The Journal of Toxicological Sciences
|September 6, 2005
Summary
This study validates a telemetry system in guinea pigs for drug-induced QT interval evaluation. The model accurately identified compounds affecting the human QT interval, showing its utility in early drug development.
Area of Science:
- Pharmacology
- Cardiovascular Research
- Drug Safety Evaluation
Background:
- Assessing drug-induced QT interval prolongation is crucial for cardiac safety.
- Existing preclinical models have limitations in predicting human cardiac effects.
- A reliable animal model for early-stage drug development is needed.
Purpose of the Study:
- To evaluate a telemetry system for QT interval assessment in conscious, free-moving guinea pigs.
- To determine the utility of this model using well-characterized reference compounds.
- To explore the model's applicability in early drug development.
Main Methods:
- Implantation of telemetry transmitters in male Hartley guinea pigs.
- Measurement of RR and QT intervals following administration of 10 reference compounds (8 positive, 2 negative).
- Pharmacokinetic analysis for positive reference compounds and assessment of QTc changes and T-wave morphology.
Main Results:
- All 8 positive reference compounds significantly prolonged the corrected QT (QTc) interval by ≥10%.
- Anticlockwise hysteresis loops were observed between QTc changes and serum concentrations for positive references.
- Negative reference compounds did not prolong QTc, and T-wave shape changes were noted with haloperidol.
Conclusions:
- The guinea pig telemetry model effectively evaluates drug-induced QT prolongation.
- The model's predictive capability is supported by its similarity to human cardiac action potentials.
- This system offers a valuable tool for preclinical cardiac safety assessment in drug development.